Alpha-1 antitrypsin deficiency (aatd)
Drug research and approvals for alpha-1 antitrypsin deficiency (aatd): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 23 studies of alpha-1 antitrypsin deficiency (aatd) are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 0 approved and 14 open orphan designations naming it.
- Recruiting worldwide: 23
- Trials authorized in Canada: 8
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 23 recruiting on ClinicalTrials.gov ↗- A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With…NCT07850076 · Phase 1 / Phase 2 · CRISPR Therapeutics · starts Dec 1, 2026
- Chronic Respiratory Disease Participant Engagement StudyNCT07924462 · Not reported · Richmond Research Institute · starts Nov 1, 2026
- Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza…NCT07326592 · Phase 4 · CSL Behring · starts Sep 29, 2026
- IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel SyndromeNCT07707635 · Not applicable · Ariel University · starts Jul 19, 2026
- A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15%…NCT07555483 · Phase 3 · Grifols Therapeutics LLC · starts May 5, 2026
- A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)NCT07227207 · Phase 1 / Phase 2 · Tessera Therapeutics, Inc. · starts Apr 21, 2026
- A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)NCT07431112 · Phase 1 · AIRNA Corporation · starts Mar 17, 2026
- Development of a Prediction Score for the Occurrence of Death or Lung Transplantation in Patients With Emphysema…NCT07715617 · Not reported · University Hospital, Bordeaux · starts Feb 16, 2026
- Genetic Variation in IgG in Alpha 1 Antitrypsin DeficiencyNCT07135427 · Phase 4 · University of Alabama at Birmingham · starts Sep 3, 2025
- Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway ObstructionNCT07152834 · Not reported · Muğla Sıtkı Koçman University · starts Aug 6, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Apr 25, 2024 | A phase 1b/2a open-label single ascending doses (sad) and multiple ascending doses (mad) research study to evaluate safety, tolerability, pharmacokinetics and…WVE-006 | WAVE LIFE SCIENCES UK LTD | Ongoing |
| Sep 18, 2023 | A phase 2, open-label study evaluating efficacy and safety of vx-864 in subjects with alpha-1 antitrypsin deficiency who have the pizz genotype, over 48 weeksVX-864 | Vertex Pharmaceuticals | Closed |
| Jan 24, 2023 | A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of fazirsiran in the treatment of alpha-1 antitrypsin…FAZIRSIRAN (TAK-999) | Takeda Pharmaceuticals USA | Ongoing |
| Aug 5, 2020 | A phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of vx-864 in pizz subjectsVX-864 | Vertex Pharmaceuticals | Closed |
| Dec 27, 2019 | A phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of vx-814 in pizz subjectsVX-814 | Vertex Pharmaceuticals | Closed |
| Jul 31, 2019 | A placebo-controlled, multi-dose, phase 2/3 study to determine the safety, tolerability and effect on liver histologic parameters in response to aro-aat in…ARO-AAT (ADS-001) | ARROWHEAD PHARMACEUTICALS, INC. | Ongoing |
| Aug 22, 2018 | A phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic…ALVELESTAT (MPH966) | MEREO BIOPHARMA 4 LTD | Closed |
| Jul 5, 2016 | An open-label, multi-dose, phase 2 study to determine the safety, tolerability and effect on circulating and intrahepatic alpha-1 antitrypsin levels of arc-aat…ARC-AAT | ARROWHEAD PHARMACEUTICALS, INC. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Nov 19, 2025 | RNA editing antisense oligonucleotide (ASO)treatment of alpha-1 antitrypsin deficiency.” | AIRNA Corporation | Designated |
| Nov 6, 2025 | in vivo target-primed reverse transcription genome editing…treatment of alpha-1 antitrypsin deficiency (AATD) | Tessera Therapeutics, Inc. | Designated |
| May 28, 2025 | a lipid nanoparticle-based therapy consisting of a guide…treatment of alpha-1 antitrypsin deficiency | Beam Therapeutics | Designated |
| Apr 9, 2025 | lipid nanoparticles containing base editor CRISPR-Cas9…treatment of alpha-1 antitrypsin deficiency | Yoltech Therapeutics Co., Ltd | Designated |
| Mar 12, 2025 | RNA editing antisense oligonucleotide (ASO) KB100967…treatment of alpha-1 antitrypsin deficiency (AATD) | Korro Bio, Inc. | Designated |
| Dec 12, 2023 | oxoindoline carboxamide compoundTreatment of alpha-1 antitrypsin deficiency | BioMarin Pharmaceutical Inc. | Designated |
| Sep 1, 2023 | A replication-defective, non-integrating herpes simplex…Treatment of Alpha-1 antitrypsin deficiency | Krystal Biotech, Inc. | Designated |
| Mar 2, 2022 | IgG4 Fc linked recombinant human AAT (alpha-1 antitrypsin)Treatment of Congenital Alpha-1 Antitrypsin Deficiency (AATD) | Sanofi Aventis US. LLC (A Sanofi Company) | Designated |
| Oct 25, 2021 | AlvelestatTreatment of Alpha-1 Antitrypsin Deficiency | Mereo Biopharma 4 Limited | Designated |
| Oct 19, 2020 | CHO cell line produced human Alpha-1 Antitrypsin (CHO-AAT)…treatment of alpha-1 antitrypsin deficiency | Caravella Biopharma SA | Designated |
| Feb 19, 2020 | Recombinant human alpha-1 antitrypsin from Oryza sativaTreatment of alpha-1 antitrypsin deficiency | Wuhan Healthgen Biotechnology Corporation | Designated |
| Feb 14, 2018 | double stranded oligomer ADS-001 RNA interference-based…Treatment of alpha-1 antitrypsin deficiency | Takeda Development Center Americas, Inc. | Designated |
| Mar 19, 2002 | hyaluronic acidTreatment of emphysema in patients due to alpha-1 antitrypsin deficiency | CoTherix | Designated |
| Mar 29, 1991 | Recombinant secretory leucocyte protease inhibitorTreatment of congenital alpha-1 antitrypsin deficiency. | Amgen Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA